How much funding has Zentalis Pharmaceuticals raised?

Zentalis Pharmaceuticals has raised $85.0M in total funding, most recently a Series C round.

Who are Zentalis Pharmaceuticals's investors?

Zentalis Pharmaceuticals's investors include Pfizer Ventures, Redmile Group.

When was Zentalis Pharmaceuticals founded?

Zentalis Pharmaceuticals was founded in 2014.

Where is Zentalis Pharmaceuticals headquartered?

Zentalis Pharmaceuticals is headquartered in San Diego, California, United States.

What industry is Zentalis Pharmaceuticals in?

Zentalis Pharmaceuticals operates in Healthcare, Biotech.

How many employees does Zentalis Pharmaceuticals have?

Zentalis Pharmaceuticals has 51-200 employees.

Zentalis Pharmaceuticals

IPO

Clinical oncology innovator

Public · San Diego, United States · Founded 2014 · $85.0M raised

Healthcare

Biotech

Headquarters: San Diego, California
Employees: 51–200
Founded: 2014
Business Model: B2B
Website: zentalis.com

Total Funding: $85.0M
Last Round: $85.0M Series CDec 2019
Rounds: 1
Type: Public

About

Zentalis Pharmaceuticals is a clinical-stage oncology company focused on developing internally discovered small molecule cancer therapies. The company's lead program is an investigational WEE1 inhibitor being evaluated for ovarian cancer and multiple other tumor types, with a Phase 3 clinical trial (ASPENOVA) initiated in 2026. Founded in 2014 and headquartered in San Diego, California, Zentalis is led by a seasoned team of oncology executives with experience advancing drugs from discovery through regulatory approval and commercial launch.

Summary

Zentalis Pharmaceuticals is a Healthcare company based in San Diego, United States, founded in 2014. It has raised $85.0M in total across 1 round, most recently a $85.0M Series C round in Dec 2019. Investors include Pfizer Ventures and Redmile Group.